Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Study Identifies Novel Chemicals Targeting Cancer Stem Cells

Published: Wednesday, November 28, 2012
Last Updated: Wednesday, November 28, 2012
Bookmark and Share
Verastem, Inc., announced that researchers have published a study utilizing the cancer stem cell screening assay exclusively licensed to Verastem to identify novel chemicals that preferentially kill cancer stem cells.

Published in the Journal of Biomolecular Screening, researchers at the Broad Institute of Harvard University and the Massachusetts Institute of Technology utilized the screen originally developed in the laboratories of Verastem scientific cofounders Robert Weinberg, Ph.D. and Eric Lander, Ph.D. Due to the difficulty in propagating cancer stem cells outside of the tumor environment, the researchers created unique cancer stem cell-like cells and used phenotypic high-throughput screening to evaluate 300,718 compounds for their ability to preferentially kill cancer stem cells. The screen identified 2,244 hits and further characterized selective compounds.

“This study demonstrates the power of the cancer stem cell screening technology that was developed by our founders and underpins our research at Verastem,” said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research. “To date, innovation in cancer therapy has been limited by a myopic focus only on targeting bulk tumor cells with little regard for resistant cancer stem cell populations. Verastem is harnessing the power of cancer stem cell-directed screens to identify novel drugs that have the ability to kill the cellular components of the tumor that resist current therapies and drive tumor recurrence.”

The top three chemical series described in the current study are exclusively licensed to Verastem and are part of a portfolio of drugs being advanced for the treatment of a broad range of cancer indications.
Verastem has built a pipeline of novel chemical series that have demonstrated the unique ability to kill cancer stem cells and plans to enter into multiple clinical studies, including a potential registration study in mesothelioma, over the next 12 months.

The article is titled “Phenotypic High-Throughput Screening Elucidates Target Pathway in Breast Cancer Stem-Like Cells.” View the complete text of the study at

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos